Michigan Medicine

Hospital M&A Activity Slowed in Q4:2022, According to Acquisition Data from LevinPro HC

Retrieved on: 
Thursday, January 12, 2023
Mediclinic International, Hospital, Yale New Haven Health System, University, OhioHealth, Housing, Mediterranean Shipping Company, Pressure, Medical Properties Trust, Walgreens, Bed, Collection, HC, Michigan Medicine, Organization, CVS, Health, Intelligence, Research, Acquisition, Health care, Sparrow Health System, Pharmaceutical industry

NEW CANAAN, Conn., Jan. 12, 2023 /PRNewswire-PRWeb/ -- Headwinds and market challenges took a toll on Hospital M&A activity in the fourth quarter of 2022. According to new acquisition data captured in the LevinPro HC platform, there were 19 transactions announced in the Hospital sector in Q4:22, a 10% decline from activity in Q3:22 when 21 deals were announced. Fourth quarter activity was virtually level with Q4:21 transaction volume when 18 deals were announced.

Key Points: 
  • Hospital M&A activity slowed in Q4:2022, according to acquisition data from LevinPro HC.
  • NEW CANAAN, Conn., Jan. 12, 2023 /PRNewswire-PRWeb/ -- Headwinds and market challenges took a toll on Hospital M&A activity in the fourth quarter of 2022.
  • According to new acquisition data captured in the LevinPro HC platform, there were 19 transactions announced in the Hospital sector in Q4:22, a 10% decline from activity in Q3:22 when 21 deals were announced.
  • Fourth quarter activity was virtually level with Q4:21 transaction volume when 18 deals were announced.

 GigXR HoloScenarios Named to TIME’s List of the Best Inventions of 2022; Recognizes Holographic Patient Simulation as Life-Changing Innovation

Retrieved on: 
Thursday, November 10, 2022
Technology, Training, Communications, Health Technology, Defense, Artificial Intelligence, Government Technology, Research, Media, Hospitals, University, Education, Health, Practice Management, Apps, Applications, General Health, Audio, Video, Science, Other Technology, Telecommunications, Telemedicine, Virtual Medicine, Software, Publishing, Cambridge Biomedical Campus, AstraZeneca, Hospital, Carbon, Gig, Cambridge University Hospitals NHS Foundation Trust, Anesthesiology, 3D, TIME, Extended reality, Partnership, Communication, Education, Health, Catalog, Department, NIHR, CBC, Technology, Smartphone, Invention, Internet access, Department of Defense Serum Repository, XR, Royal Papworth Hospital, CUH, Cambridge University Health Partners, University, Trauma, Atmosphere, Solution, CA, Rosie Hospital, Asthma, Consultant, NHS, Anaphylaxis, Pulmonary embolism, Michigan Medicine, Patient, Judgement, Heart, CEO, Medicine, Medical device, Neuroscience, Campus

GigXR, Inc. , a global provider of holographic healthcare training, announced today that its mixed reality patient training application, HoloScenarios, has been awarded TIMES 2022 Best Inventions .

Key Points: 
  • GigXR, Inc. , a global provider of holographic healthcare training, announced today that its mixed reality patient training application, HoloScenarios, has been awarded TIMES 2022 Best Inventions .
  • To ensure medical integrity and realism of HoloScenarios, GigXR partners with healthcare subject matter experts to inform and guide the creation of the holographic simulations.
  • We couldnt be more honored to share TIMES 2022 Best Inventions Award with the team and technologists at GigXR.
  • To see the full list of TIMEs List of the Best Inventions of 2022, visit time.com/best-inventions-2022 .

Fractyl Health Initiates Landmark Scientific Partnership to Study Root Cause Mechanisms Underlying Type 2 Diabetes

Retrieved on: 
Wednesday, November 2, 2022
Health, Diabetes, Entrepreneurship, Duke University School of Medicine, CEO, Mortality, Partnership, Division, Research, Metabolism, Health, Disease, Michigan Medicine, Biophysics, Duodenum, University, Catholic higher education, Vanderbilt University, Internal medicine, Associate, FDA, Union, Insulin, Patient, Vanderbilt University School of Medicine, University of Michigan, Therapy, Pharmaceutical industry, Medical device, T2D, Endocrinology, Medicine, Diabetes

These two scientific research initiatives will establish a foundation of new evidence on nutrient sensing and signaling mechanisms in a segment of the intestine called the duodenum.

Key Points: 
  • These two scientific research initiatives will establish a foundation of new evidence on nutrient sensing and signaling mechanisms in a segment of the intestine called the duodenum.
  • In spearheading this partnership, Fractyl Health is enthusiastic to begin this effort with academic partners who are icons in the field.
  • Our ambition is to support the deep science that will lead to a greater understanding of the root causes of T2D.
  • Fractyl Health is focused on pioneering a new approach to the treatment of T2D.

Closing Chronic Wounds with Collagen Powder: University of Michigan case study demonstrates the efficacy of ColActive Plus Powder in resolving non-healing wounds

Retrieved on: 
Tuesday, November 1, 2022
Growth, CEO, CWSP, News, Wound healing, Moyamoya disease, FACPM, Amputation, Risk, TSX Venture Exchange, Michigan Medicine, COV, Phrase, University, University of Michigan School of Information, Company, Patient, SAWC, Quality of life, Forward-looking statement, Symposium, Infection, DPM, Conditional sentence, Pharmaceutical industry, Silk, Collagen

The study, conducted by Dr. Alton Johnson Jr., DPM, FACPM, DABPM, CWSP,at University of Michigan School of Medicine, demonstrates the efficacy of ColActive Plus Powder in treating chronic non-healing wounds.

Key Points: 
  • The study, conducted by Dr. Alton Johnson Jr., DPM, FACPM, DABPM, CWSP,at University of Michigan School of Medicine, demonstrates the efficacy of ColActive Plus Powder in treating chronic non-healing wounds.
  • "I've had success using the ColActive Plus Powder to close challenging stalled wounds.
  • "In just a short time on the market, ColActive Plus Powder has become known as a "closer" of challenging wounds.
  • Treatment with weekly pulse lavage and ColActive Plus Powder resulted in the chronic post-amputation wounds being closed within 28 days, remaining healed to date.

Surgical experts publish updated MRONJ guidance

Retrieved on: 
Tuesday, October 18, 2022
Quality of life, Dentist, Element, Disease, Medicine, Risk, Health care, The Stony Brook School, Infection, American Association of Oral and Maxillofacial Surgeons, UCLA School of Dentistry, Alveolar osteitis, Patient, Osteoporosis, Oral and maxillofacial surgery, Journal of Oral and Maxillofacial Surgery, Necrosis, University, MPH, Oncology, Jaw, Collection, Inflammation, Exhibition, Dental care, Knowledge, Dentistry, Immune system, Commonly used gamma-emitting isotopes, Rheumatology, Oral hygiene, Doctor of Philosophy, Extraction (chemistry), American Association, Oral, Degenerative disease, Association, Committee, Face, Sinusitis, Michigan Medicine, Carlson, Journal, EDM, Gingivitis, Head, Literature, Tobacco, AAOMS, North Memorial Health Hospital, Reconstructive surgery, Cancer, Algorithm, Medical device, MRONJ, DMD, MD, DRS, DDS

ROSEMONT, Ill., Oct. 18, 2022 /PRNewswire/ -- The American Association of Oral and Maxillofacial Surgeons (AAOMS) has issued updated guidance for treating a rare but potentially serious jawbone condition that can impact patients taking antiresorptive medications to treat certain cancer types.

Key Points: 
  • To help patients and healthcare providers navigate this clinical concern, oral and maxillofacial surgery experts analyzed literature and revised guidance to reflect current best practices.
  • Among strategies for reducing the risk of MRONJ: maintaining good oral hygiene, performing high-risk surgical procedures prior to initiating drug therapies, quitting smoking and optimizing diabetes care.
  • Surgical management of MRONJ is increasingly considered a viable method of treatment for all stages of the disease, according to the 2022 guidance.
  • A departure from the three previous position papers, the 2022 recommendations recognize the value of surgical intervention regardless of MRONJ disease stage.

Vituity to Provide Emergency Services at Sparrow Health System's New Freestanding Emergency Department in Okemos

Retrieved on: 
Monday, September 19, 2022
AL, Culture, Center, DO, Sparrow Health System, Hospital medicine, Partnership, Learning, Michigan Medicine, Patient, Michigan State University College of Osteopathic Medicine, Emergency medicine, Physician, Standard of care, Leadership, Caregiver, GLOBE, Hospital, Medicine, Sparrow

Beginning Sept. 13, a Vituity team of locally based clinicians began staffing and managing a freestanding emergency department to augment the hospital's acute care services.

Key Points: 
  • Beginning Sept. 13, a Vituity team of locally based clinicians began staffing and managing a freestanding emergency department to augment the hospital's acute care services.
  • Today, Vituity works in six Sparrow facilities, providing emergency and hospital medicine and tele-infectious disease services that benefit communities throughout Michigan.
  • "We're excited to partner once again with Vituity and expand emergency care services throughout our Michigan communities," said Denny Martin, DO, E.W.
  • "Vituity is excited to expand our partnership with Sparrow Health System and deliver effective acute care services to the Okemos community," said Eric Mallet, M.D., Division Vice President at Vituity.

Michigan Medicine Modernizes Digital Experience for Healthcare Consumers in Expansion with Loyal

Retrieved on: 
Wednesday, September 7, 2022
University, COVID-19, CEO, Technology, Research, University of Michigan Rogel Cancer Center, News, Solution, Michigan Medicine, Cone Health Women's Hospital, Physician, Teaching hospital, U.S. News & World Report, Hospital, C.S. Mott Children's Hospital, Health, Metro Health Hospital, Mental health, Ann, Marketing, COVID, AI, Patient, Pharmaceutical industry, Loyal, Deloitte

ATLANTA, Sept. 7, 2022 /PRNewswire/ -- Following the success of Michigan Medicine's chatbot during the COVID-19 pandemic, the Ann Arbor-based academic medical center has agreed to a three-year contract to expand its relationship with Loyal, the preferred digital health platform for the nation's leading health systems and hospitals.

Key Points: 
  • Michigan Medicine will soon expand its chatbot to answer consumer questions about locations and relevant providers, billing and payments, and long-term COVID support services.
  • This addition to Michigan Medicine's existing AI technology will more efficiently recognize consumers' intent, point them to answers and provide the information they need.
  • "Consumers today have different expectations of healthcare providers; they want a digital experience that's personalized and meets their immediate needs," said Chad Mallory, CEO of Loyal.
  • Michigan Medicine includes the top ranked U-M Medical School and University of Michigan Health, which includes the C.S.

Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

Retrieved on: 
Tuesday, August 30, 2022
Harvard Medical School, Health care, Mayo Clinic, Huntingdon Life Sciences, University, Houston Methodist Hospital, Diarrhea, Technology, Pain, European Technology Platform on Smart Systems Integration, Time, Calendar, Sale, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Michigan Medicine, Private Securities Litigation Reform Act, Physician, GI, LDT, Biomedical technology, Diet, Bloating, Patent, List of life sciences, CLIA, GLOBE, Hospital, Nasdaq, Company, FDA, Constipation, IBS, Prometheus, Knowledge, Clinical trial, Health, Growth, Environment, Marketing, Patient, Medicine, Pharmaceutical industry, Gastroenterology

The Company further announced it has hired Robert Carlson to serve as the Companys Chief Commercial Officer in preparation for the launch of InFoods IBS.

Key Points: 
  • The Company further announced it has hired Robert Carlson to serve as the Companys Chief Commercial Officer in preparation for the launch of InFoods IBS.
  • The commercial launch of the InFoods IBS test is expected before calendar year-end 2022.
  • Mr. Carlson will manage the immediate logistics of the LDT launch, and drive the mid-term InFoods IBS commercialization strategy including national reimbursement and FDA marketing authorization.
  • Robert Carlson, Biomerica Chief Commercial Officer said, The InFoods platform technology has the potential to greatly improve how IBS and other diseases are managed, as it enables physicians to provide personalized medicine for their patients.

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Retrieved on: 
Wednesday, August 3, 2022
European Medicines Agency, Cisplatin, MDS, Acute myeloid leukemia, Patient, Food, Survival, EMA, Hope, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Progression-free survival, FDA, Pancreatic cancer, Cancer, TCA, University of Michigan Rogel Cancer Center, Enzyme, Research, Michigan Medicine, Peripheral T-cell lymphoma, Myelodysplastic syndrome, Therapy, GLOBE, CEO, Mitochondrion, Devimistat, University, Cholangiocarcinoma, Terminology, Pharmaceutical industry, Medical imaging, MBBS

In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

Key Points: 
  • In collaboration with Michigan Medicine , the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer.
  • The Phase 1b portion of the trial enrolled 20 patients and concluded that the combination of gemcitabine and cisplatin with devimistat is well tolerated.
  • The randomized Phase 2 portion of the trial is open and accruing patients across 10 cancer centers in the U.S., targeting an enrollment of 78 patients.
  • Advanced biliary tract cancer is a rare and aggressive form of cancer with a 5-year survival rate of less than 5%.

Chemotherapy Drugs from "Rogue" Online Pharmacies Could Endanger Leukemia Patients, Suggests Research in JNCCN

Retrieved on: 
Thursday, July 28, 2022
Online, Patient, CPP, Health care, University, Education, DuckDuckGo, Acute leukemia, Associate professor, Physician, National Comprehensive Cancer Network, CML, Harborside, Twitter, LegitScript, Doctor of Philosophy, Health, Research, Leukemia, Patient safety, UNC Eshelman School of Pharmacy, Medicine, MHS, Safety, Public policy, Michigan Medicine, Cancer, Report, Oncology, Policy, Review, Strathcona County, NCCN, Caregiver, Assistant professor, Journal of the National Comprehensive Cancer Network, URL, Doctor of Pharmacy, Lymphatic system, Hope, Yahoo!, Google, Investor, Decision-making, Bioethics, Pharmaceutical industry, Health insurance, Medical device, Pharmacy

PLYMOUTH MEETING, Pa., July 28, 2022 /PRNewswire/ -- Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network. A survey of online pharmacies claiming to sell the oral chemotherapy drug imatinib found that only three of the 44 identified English-language sites that shipped within the United States were certified through the LegitScript online pharmacy monitoring service. A full 52% were classified as "rogue" pharmacies that might operate without a license, sell counterfeit or expired products, steal users' payment information, or reject important safety precautions like requiring a prescription for potentially hazardous medications. 

Key Points: 
  • A new study finds a majority of online pharmacies selling the chronic myeloid leukemia therapy imatinib are uncertified and could be operating unsafely.
  • Tyrosine kinase inhibitors like imatinib have made chronic myeloid leukemia (CML) a manageable condition rather than a fatal one.
  • Yet to work optimally, the drug must be taken for the rest of a patient's life and with high compliance.
  • Complimentary access to " Online Pharmacy Accessibility of Imatinib, An Oral Chemotherapy Medication " is available until October 10, 2022.